Clinical Trials


Taste Properties of HIV Inhibitor

This study has been completed
ViiV Healthcare

Senopsys, LLC

Information provided by (Responsible Party)
ViiV Healthcare Identifier

First received: November 17, 2015
Last updated: April 13, 2018
Last Verified: April 2018
History of Changes


The purpose of the study is to assess the taste properties of HIV inhibitor

Condition Intervention Phase
HIV Infections

Drug : BMS-955176
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open-Label Taste Assessment of BMS-955176 in Healthy Subjects

Further study details as provided by ViiV Healthcare:

Primary Outcome Measures

  • Taste properties of HIV Inhibitor will be measured using the Flavor Profile of the Flavor Leadership Criteria [ Time Frame: Up to 2 years ]

Enrollment: 8
Study Start Date: January 5, 2016
Study Completion Date: May 24, 2016
Primary Completion Date: May 24, 2016 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: BMS-955176
BMS-955176 specified dose on specified days
Drug: BMS-955176
Other Name: HIV Maturation Inhibitor


Ages Eligible for Study: 25 Years to 80 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: Yes  


For more information regarding BMS clinical trial participation, please visit
Inclusion Criteria:

  • Men and women of non-childbearing potential professional sensory panelists
  • Aged between 25 and 80 years

Exclusion Criteria:
  • History of relevant drug or food allergies, cardiovascular or Central nervous system (CNS) disease, clinically significant pathology, history of mental illness
  • Positive HIV test

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02608918


United States, Massachusetts
GSK Investigational Site
Woburn, Massachusetts, United States, 01801

Sponsors and Collaborators

ViiV Healthcare
Senopsys, LLC


Study Director: Viiv Clinical Trials ViiV Healthcare
More Information

More Information

Additional Information:

BMS clinical trial educational resource

Additional Information:

Investigator Inquiry form

Additional Information:

FDA Safety Alerts and Recalls

Responsible Party: ViiV Healthcare Identifier: NCT02608918   History of Changes  
Other Study ID Numbers: 206301  
Study First Received: November 17, 2015  
Last Updated: April 13, 2018  

Additional relevant MeSH terms:
HIV Infections processed this data on July 20, 2018
This information is provided by